Review on 3D Printing Regulation in Pharmaceutical in India

Abstract

Three-dimensional printing (3DP), also known as additive manufacturing (AM), is a revolutionary technology model changing pharmaceutical manufacturing, enabling personalized scalable construction of complex topic drug products in the lab to full fill customized patient prescriptions. This review outlines the history of 3DP, beginning with photopolymer printing in the 1960s and continuing through to the FDA approved 3D-printed tablet product, Spritam, in 2016. The information technologies—include the inkjet printing, stereolithography (SLA), and fused deposition modelling (FDM)/hot melt extrusion (HME)—are discussed, emphasizing their work capability in detail, along with incorporating their benefits tangibility enhancement and taste desensitization along with as well. There are requirements posed in recent research (i.e., warm property, polymer accessibility). Recent advances show promise that 3DP can prepare novel drug delivery systems composed of sophisticated architectures such as tablets with compositions of gradient.